These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 2082904

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. [Treatment of essential hyperlipidemia with procetofene. Apropos of 100 cases].
    Fromantin M, Gautier D, Bon R.
    Sem Hop Ther; 1977; 53(5-6):311-6. PubMed ID: 897691
    [No Abstract] [Full Text] [Related]

  • 45. A symposium: lipid management summit on improving practice outcome. Introduction.
    Ballantyne CM.
    Am J Cardiol; 2000 Feb 10; 85(3A):1A-2A. PubMed ID: 10695700
    [No Abstract] [Full Text] [Related]

  • 46. Current and future therapeutic approaches to hyperlipidemia.
    Farmer JA, Gotto AM.
    Adv Pharmacol; 1996 Feb 10; 35():79-114. PubMed ID: 8920205
    [No Abstract] [Full Text] [Related]

  • 47. How should HIV patients lower lipid levels?
    Brown BR.
    HIV Clin; 2000 Feb 10; 12(3):1, 6-8. PubMed ID: 11810836
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM.
    Kardiologiia; 2004 Feb 10; 44(3):87-93. PubMed ID: 15489838
    [No Abstract] [Full Text] [Related]

  • 51. [Anti-hyperlipidemic agents].
    Kinoshita M.
    Nihon Rinsho; 2002 May 10; 60(5):968-74. PubMed ID: 12030001
    [Abstract] [Full Text] [Related]

  • 52. Assessment and management of vascular disease risk in patients with chronic kidney disease.
    Brown WV, Bakris G, Lerma E, Chertow G.
    J Clin Lipidol; 2011 May 10; 5(4):251-60. PubMed ID: 21784369
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Drug intervention trials in dyslipidemia: the past and the future.
    Dujovne CA.
    Clin Cardiol; 1991 Feb 10; 14(2 Suppl 1):I48-52. PubMed ID: 2044259
    [Abstract] [Full Text] [Related]

  • 55. Treatment of hyperlipidaemia as a risk factor for coronary heart disease: the role of fibrates.
    Linssen R.
    Hosp Med; 1999 Apr 10; 60(4):298-301. PubMed ID: 10396439
    [No Abstract] [Full Text] [Related]

  • 56. Treatment of hyperlipidemia in nephrotic syndrome: time for a change?
    Olbricht CJ, Koch KM.
    Nephron; 1992 Apr 10; 62(2):125-9. PubMed ID: 1436302
    [No Abstract] [Full Text] [Related]

  • 57. [The mechanisms of action of etophylline-clofibrate in hyperlipidemia].
    Păduraru I, Nechifor M, Dănilă G, Jercă L, Filip M, Iacobovici A, Teslaru E, Filip C, Saramet A.
    Rev Med Chir Soc Med Nat Iasi; 1993 Apr 10; 97(1):445-9. PubMed ID: 8153471
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Hyperlipidemia therapy: can it prevent coronary atherosclerosis?
    Nash DT.
    Postgrad Med; 1982 Aug 10; 72(2):207-11. PubMed ID: 7100012
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.